Early Trials of PRMT5 Inhibitors Leave Much to Be Desired, But Optimism Remains
Despite the discovery of protein arginine methyltransferase 5 more than 20 years ago, interest in the potential oncogene as a treatment target for patients with hematologic and solid malignancies has increased in recent years with the advancement of multiple novel agents through preclinical and early-phase studies.
Source: onclive.com
